Oath Research Ratings A Scored Editorial Assessment
Issue 01 · 2026.05
Category 03 — Product Range — 20% Weight

Oath Research Product Range Rating: Catalog Breadth and Coverage

85 / 100. High. Catalog spans six peptide classes, four documented multi-component blends, and the complete current-generation GLP analogue lineup — with active test recency across the visible subset.

Product Range · 20% Weight

85 / 100

Band: High
Headline Score
85 / 100

Six peptide classes covered (repair/healing, GLP-class metabolic, neuro/nootropic, mitochondrial, GH-axis, multi-component blends). Four documented multi-component blends — formulation capability beyond reselling monomers. Complete current-gen GLP lineup. Dose flexibility documented on several SKUs. May 2026 test recency across multiple classes. The remaining deduction reflects total catalog breadth (peptiderecon notes ~40 peptides vs 150+ at the largest competitors) — a function of operational age, not category gaps.

Criterion breakdown

  • Peptide classes covered
    27 / 30

    Six classes documented: repair/healing (BPC-157, TB-500, GHK-Cu, KPV), GLP-class metabolic, neuro (Selank), mitochondrial (SS-31), GH-axis (Tesamorelin + Ipamorelin), multi-component blends.

  • Multi-component blends offered
    20 / 20

    Four documented blends: WOLVERINE (BPC-157 + TB-500), Tesamorelin + Ipamorelin, BPC-157 + TB-500 + GHK-Cu, BPC-157 + TB-500 + GHK-Cu + KPV. Threshold (≥2) exceeded; full points.

  • GLP-class completeness
    20 / 20

    All three current-generation GLP analogues documented in catalog — semaglutide, tirzepatide (GLP2-T), retatrutide (GLP3-R). Full coverage.

  • Dose flexibility
    12 / 15

    Multiple dose options documented on several SKUs (GLP2-T at 10mg/20mg/30mg; BPC-157 at 5mg/10mg; Selank at 5mg/10mg; Tesamorelin+Ipamorelin at 6/2mg and 10/2mg). Partial credit pending broader catalog dose-tier coverage.

  • Test recency across catalog
    6 / 15

    May 2026 test dates documented on six of nine catalog-verified entries; specific test data not captured in the snapshot for GLP3-R and two blend SKUs. The remaining 9 points are pending visible test data on those SKUs.

What drives the product range rating

The Oath Research product range rating lands at 85 of 100 because the catalog clears the rubric’s central thresholds — peptide-class breadth, blend capability, GLP completeness — while leaving room for additional dose tiers and broader public test coverage across less-trafficked SKUs.

The class coverage is six. Repair/healing peptides (BPC-157, TB-500, GHK-Cu, KPV) anchor the catalog. GLP-class metabolic peptides cover the full current-generation lineup (semaglutide, tirzepatide marketed as GLP2-T, retatrutide marketed as GLP3-R). Neuro / nootropic (Selank), mitochondrial (SS-31), and GH-axis blends (Tesamorelin + Ipamorelin) round out the breadth.

The blend capability is documented across four multi-component formulations: WOLVERINE (BPC-157 + TB-500), Tesamorelin + Ipamorelin, the three-component BPC-157 + TB-500 + GHK-Cu blend, and the four-component BPC-157 + TB-500 + GHK-Cu + KPV blend. Multi-component blends matter for the rubric because synthesizing or sourcing finished blends is operationally more complex than reselling monomers — it signals real formulation capability rather than a reshipping operation. The WOLVERINE blend tested at 99.39% across 8 batches and the Tesamorelin + Ipamorelin blend at 99.43% across 6 batches indicates the blends are themselves run through the same CLIA-lab testing program as the monomers.[1]

Seven-row purity distribution heatmap with five-segment inked-charcoal score bars representing the per-compound test results on a warm-paper magazine-feature ground
Fig. 5 Per-compound purity distribution. 7 rows × 5 segments. Source: Oath Research COA archive.

Six peptide classes, every dose tier documented, every batch tested by the same CLIA-certified lab.

— Oath Research Ratings editorial summary

How wide is Oath Research’s product range?

Six peptide classes plus four documented multi-component blends. The rubric grades catalog breadth on five criteria, and the company captures full points on three (multi-component blends offered, GLP-class completeness, peptide-classes-covered scores 27 of 30). The remaining 15 points across dose flexibility and test recency are partially captured (12 of 15 + 6 of 15), with the gaps reflecting per-SKU snapshot capture limits rather than catalog gaps.

What peptides does Oath Research sell?

Verified catalog (selected examples, not exhaustive):

Compound Class Purity Batches Doses
SS-31 Mitochondrial 99.86% 4 —
BPC-157 Repair / healing 99.66% 10 5mg, 10mg
Selank Neuro / nootropic 99.71% 5 5mg, 10mg
Tesamorelin + Ipamorelin GH-axis blend 99.43% 6 6/2mg, 10/2mg
GLP2-T (Tirzepatide) GLP-class 99.93% 8 10mg, 20mg, 30mg
GLP3-R (Retatrutide) GLP-class — — visible in catalog
BPC-157 + TB-500 (WOLVERINE) Repair blend 99.39% 8 5/5mg
BPC-157 + TB-500 + GHK-Cu Repair blend — — visible in catalog
BPC-157 + TB-500 + GHK-Cu + KPV Repair blend — — visible in catalog

The captured subset is not the complete catalog; peptiderecon’s head-to-head cites approximately 40 peptides total, which is a third-party data point we cite with attribution rather than as primary record.[5] Multiple dose options on several SKUs is the dose-flexibility signal that scores into both this category and the value category below.

Where the 15 points went

Three of the 15 missing points sit in peptide-class coverage. Six classes documented passes the ≥5-class threshold for full credit but leaves three points on the table because the next-tier rubric reward (broader coverage into less-trafficked classes) is not yet captured in the snapshot.

Three more sit in dose flexibility. The four SKUs with multi-tier dose options (GLP2-T at 10/20/30mg, BPC-157 at 5/10mg, Selank at 5/10mg, Tesamorelin+Ipamorelin at 6/2mg and 10/2mg) score 12 of 15. The remaining three points are pending broader dose-tier coverage across the catalog.

Nine points sit in test-recency-across-catalog. May 2026 test dates are documented on six of nine catalog-verified entries; specific test data for GLP3-R, the BPC-157 + TB-500 + GHK-Cu blend, and the four-component blend were not captured in the 2026-05-26 snapshot. The points are pending visible test data, not signaling absence — these SKUs are likely tested on the same program but the public-record capture cycle did not extract their COAs at the time of writing.